European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation

Marina Berenguer; Eleonora de Martin; Amelia J. Hessheimer; Josh Levitsky; Daniel G. Maluf; Valeria R. Mas; Nazia Selzner; Helena Hernàndez-Èvole; Alina Lutu; Nabeel Wahid; Haseeb Zubair

doi:10.3389/ti.2023.11358

European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation

Marina Berenguer^*, Eleonora de Martin, Amelia J. Hessheimer, Josh Levitsky, Daniel G. Maluf, Valeria R. Mas, Nazia Selzner, Helena Hernàndez-Èvole, Alina Lutu, Nabeel Wahid, Haseeb Zubair

^*Corresponding author for this work

Medicine, Hepatology Division

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article.

Original language	English (US)
Article number	11358
Journal	Transplant International
Volume	36
DOIs	https://doi.org/10.3389/ti.2023.11358
State	Published - 2023

Funding

All costs related to taskforce and workgroup meetings were covered by ESOT, without external funding. MB was granted by the Instituto de Salud Carlos III and co-funded by European Regional Development Fund “A way to make Europe” (grants number PI19/01360 and INT20/00061). All costs related to taskforce and workgroup meetings were covered by ESOT, without external funding. MB was granted by the Instituto de Salud Carlos III and co-funded by European Regional Development Fund “A way to make Europe” (grants number PI19/01360 and INT20/00061).

Keywords

biomarkers
chronic kidney disease
hepatocellular carcinoma
liver transplantation
recurrent primary diseases
rejection

ASJC Scopus subject areas

Transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/ti.2023.11358

Cite this

@article{e81ce449f78d4183be585e2479e18676,

title = "European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation",

abstract = "Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article.",

keywords = "biomarkers, chronic kidney disease, hepatocellular carcinoma, liver transplantation, recurrent primary diseases, rejection",

author = "Marina Berenguer and {de Martin}, Eleonora and Hessheimer, {Amelia J.} and Josh Levitsky and Maluf, {Daniel G.} and Mas, {Valeria R.} and Nazia Selzner and Helena Hern{\`a}ndez-{\`E}vole and Alina Lutu and Nabeel Wahid and Haseeb Zubair",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 Berenguer, de Martin, Hessheimer, Levitsky, Maluf, Mas, Selzner, Hern{\`a}ndez-{\`E}vole, Lutu, Wahid and Zubair.",

year = "2023",

doi = "10.3389/ti.2023.11358",

language = "English (US)",

volume = "36",

journal = "Transplant International",

issn = "0934-0874",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation

AU - Berenguer, Marina

AU - de Martin, Eleonora

AU - Hessheimer, Amelia J.

AU - Levitsky, Josh

AU - Maluf, Daniel G.

AU - Mas, Valeria R.

AU - Selzner, Nazia

AU - Hernàndez-Èvole, Helena

AU - Lutu, Alina

AU - Wahid, Nabeel

AU - Zubair, Haseeb

PY - 2023

Y1 - 2023

N2 - Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article.

AB - Currently, one-year survival following liver transplantation (LT) exceeds 90% in large international registries, and LT is considered definitive treatment for patients with end-stage liver disease and liver cancer. Recurrence of disease, including hepatocellular carcinoma (HCC), significantly hampers post-LT outcomes. An optimal approach to immunosuppression (IS), including safe weaning, may benefit patients by mitigating the effect on recurrent diseases, as well as reducing adverse events associated with over-/under-IS, including chronic kidney disease (CKD). Prediction of these outcome measures—disease recurrence, CKD, and immune status—has long been based on relatively inaccurate clinical models. To address the utility of new biomarkers in predicting these outcomes in the post-LT setting, the European Society of Organ Transplantation (ESOT) and International Liver Transplant Society (ILTS) convened a working group of experts to review literature pertaining to primary disease recurrence, development of CKD, and safe weaning of IS. Summaries of evidence were presented to the group of panelists and juries to develop guidelines, which were discussed and voted in-person at the Consensus Conference in Prague November 2022. The consensus findings and recommendations of the Liver Working Group on new biomarkers in LT, clinical applicability, and future needs are presented in this article.

KW - biomarkers

KW - chronic kidney disease

KW - hepatocellular carcinoma

KW - liver transplantation

KW - recurrent primary diseases

KW - rejection

UR - http://www.scopus.com/inward/record.url?scp=85170708589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170708589&partnerID=8YFLogxK

U2 - 10.3389/ti.2023.11358

DO - 10.3389/ti.2023.11358

M3 - Article

C2 - 37711401

AN - SCOPUS:85170708589

SN - 0934-0874

VL - 36

JO - Transplant International

JF - Transplant International

M1 - 11358

ER -

European Society for Organ Transplantation Consensus Statement on Biomarkers in Liver Transplantation

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this